Home LiteratureArticle Details
PMID: 12023945 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't

Long PDE4 cAMP specific phosphodiesterases are activated by protein kinase A-mediated phosphorylation of a single serine residue in Upstream Conserved Region 1 (UCR1).

British journal of pharmacology ·Vol. 136 ·No. 3 ·2002-06-00 ·Pages 421-33

MacKenzie SJ, Baillie GS, McPhee I, MacKenzie C, Seamons R, McSorley T, Millen J, Beard MB, van Heeke G, Houslay MD

Abstract

1. Challenge of COS1 cells with the adenylyl cyclase activator forskolin led to the activation of recombinant PDE4A8, PDE4B1, PDE4C2 and PDE4D5 cAMP-specific phosphodiesterase long isoforms. 2. Forskolin challenge did not activate mutant long PDE4 isoforms where the serine target residue (STR) within the protein kinase A (PKA) consensus phosphorylation site in Upstream Conserved Region 1 (UCR1) was mutated to alanine. 3. The PKA inhibitor, H89, ablated forskolin activation of wild-type long PDE4 isoforms. 4. Activated PKA caused the in vitro phosphorylation of recombinant wild-type long PDE4 isoforms, but not those where the STR was mutated to alanine. 5. An antiserum specific for the phosphorylated form of the STR detected a single immunoreactive band for recombinant long PDE4 isoforms expressed in COS1 cells challenged with forskolin. This was not evident in forskolin-challenged cells treated with H89. Neither was it evident in forskolin-challenged cells expressing long isoforms where the STR had been mutated to alanine. 6. In transfected COS cells challenged with forskolin, only the phosphorylated PDE4D3 long form showed a decrease in mobility in Western blotting analysis. This decreased mobility of PDE4D3 was ablated upon mutation of either of the two serine targets for PKA phosphorylation in this isoform, namely Ser54 in UCR1 and Ser13 in the isoform-specific N-terminal region. 7. Activation by forskolin challenge did not markedly alter the sensitivity of PDE4A8, PDE4B1, PDE4C2 and PDE4D5 to inhibition by rolipram. 8. Long PDE4 isoforms from all four sub-families can be phosphorylated by protein kinase A (PKA). This leads to an increase in their activity and may thus contribute to cellular desensitization processes in cells where these isoforms are selectively expressed.

MeSH Terms
3',5'-Cyclic-AMP Phosphodiesterases/genetics,immunology,metabolism Amino Acid Sequence Animals COS Cells Conserved Sequence Cyclic AMP/metabolism Cyclic AMP-Dependent Protein Kinases/metabolism Cyclic Nucleotide Phosphodiesterases, Type 4 Electrophoresis, Polyacrylamide Gel Enzyme Activation Female Immune Sera Isoenzymes/genetics,immunology,metabolism Luminescent Measurements Mutagenesis, Site-Directed Phosphodiesterase Inhibitors/pharmacology Phosphorylation Rabbits Rolipram/pharmacology Serine/metabolism
Chemicals
Immune Sera Isoenzymes Phosphodiesterase Inhibitors Serine Cyclic AMP Cyclic AMP-Dependent Protein Kinases 3',5'-Cyclic-AMP Phosphodiesterases Cyclic Nucleotide Phosphodiesterases, Type 4 Rolipram
Authors & Affiliations
10 authors, click to expand affiliations / ORCID
MacKenzie Simon J
Molecular Pharmacology Group, Division of Biochemistry & Molecular Biology, Davidson & Wolfson Buildings, Institute of Biomedical & Life Sciences, University of Glasgow, Glasgow G12 8QQ, Scotland, UK.
Baillie George S
McPhee Ian
MacKenzie Carolynn
Seamons Rachael
McSorley Theresa
Millen Jenni
Beard Matthew B
van Heeke Gino
Houslay Miles D
References (60)
60 references, click to expand
  1. Regulation of distinct cyclic AMP-specific phosphodiesterase (phosphodiesterase type 4) isozymes in human monocytic cells.
    Mol Pharmacol. 1995 Jun;47(6):1164-71 PMID: 7603456
  2. The molecular biology of cyclic nucleotide phosphodiesterases.
    Prog Nucleic Acid Res Mol Biol. 1999;63:1-38 PMID: 10506827
  3. Type III cGMP-inhibited cyclic nucleotide phosphodiesterases (PDE3 gene family).
    Cell Signal. 1995 Jul;7(5):445-55 PMID: 8562305
  4. Identification, characterization and regional distribution in brain of RPDE-6 (RNPDE4A5), a novel splice variant of the PDE4A cyclic AMP phosphodiesterase family.
    Biochem J. 1995 Sep 15;310 ( Pt 3):965-74 PMID: 7575434
  5. PDE isoenzymes as targets for anti-asthma drugs.
    Eur Respir J. 1995 Jul;8(7):1179-83 PMID: 7589403
  6. Activation and selective inhibition of a cyclic AMP-specific phosphodiesterase, PDE-4D3.
    Mol Pharmacol. 1995 Oct;48(4):616-22 PMID: 7476886
  7. Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms.
    Physiol Rev. 1995 Oct;75(4):725-48 PMID: 7480160
  8. Alternative splicing of cAMP-specific phosphodiesterase mRNA transcripts. Characterization of a novel tissue-specific isoform, RNPDE4A8.
    J Biol Chem. 1996 Jan 12;271(2):1065-71 PMID: 8557632
  9. The postsynaptic density: a subcellular anchor for signal transduction enzymes.
    Cell Signal. 1995 Nov;7(8):747-57 PMID: 8593243
  10. Phosphorylation and activation of a cAMP-specific phosphodiesterase by the cAMP-dependent protein kinase. Involvement of serine 54 in the enzyme activation.
    J Biol Chem. 1996 Jul 12;271(28):16526-34 PMID: 8663227
  11. Challenge of human Jurkat T-cells with the adenylate cyclase activator forskolin elicits major changes in cAMP phosphodiesterase (PDE) expression by up-regulating PDE3 and inducing PDE4D1 and PDE4D2 splice variants as well as down-regulating a novel PDE4A splice variant.
    Biochem J. 1997 Jan 1;321 ( Pt 1):165-75 PMID: 9003416
  12. Characterization of an intronic promoter of a cyclic adenosine 3',5'-monophosphate (cAMP)-specific phosphodiesterase gene that confers hormone and cAMP inducibility.
    Mol Endocrinol. 1997 Jun;11(7):839-50 PMID: 9178744
  13. Tailoring cAMP-signalling responses through isoform multiplicity.
    Trends Biochem Sci. 1997 Jun;22(6):217-24 PMID: 9204709
  14. Diversity in cyclic nucleotide phosphodiesterase isoenzyme families.
    Arch Biochem Biophys. 1995 Sep 10;322(1):1-13 PMID: 7574662
  15. Phosphodiesterase 4 (PDE4) inhibitors in asthma and chronic obstructive pulmonary disease (COPD).
    Prog Drug Res. 1999;53:193-229 PMID: 10616299
  16. Regulation of cAMP and cGMP signaling: new phosphodiesterases and new functions.
    Curr Opin Cell Biol. 2000 Apr;12(2):174-9 PMID: 10712916
  17. Phosphodiesterase 4 inhibitors and the treatment of asthma: where are we now and where do we go from here?
    Drugs. 2000 Feb;59(2):193-212 PMID: 10730545
  18. UCR1 and UCR2 domains unique to the cAMP-specific phosphodiesterase family form a discrete module via electrostatic interactions.
    J Biol Chem. 2000 Apr 7;275(14):10349-58 PMID: 10744723
  19. Short term feedback regulation of cAMP in FRTL-5 thyroid cells. Role of PDE4D3 phosphodiesterase activation.
    J Biol Chem. 2000 Apr 14;275(15):10831-7 PMID: 10753877
  20. ERK2 mitogen-activated protein kinase binding, phosphorylation, and regulation of the PDE4D cAMP-specific phosphodiesterases. The involvement of COOH-terminal docking sites and NH2-terminal UCR regions.
    J Biol Chem. 2000 Jun 2;275(22):16609-17 PMID: 10828059
  21. Atomic structure of PDE4: insights into phosphodiesterase mechanism and specificity.
    Science. 2000 Jun 9;288(5472):1822-5 PMID: 10846163
  22. The cAMP-specific phosphodiesterase PDE4A5 is cleaved downstream of its SH3 interaction domain by caspase-3. Consequences for altered intracellular distribution.
    J Biol Chem. 2000 Sep 8;275(36):28063-74 PMID: 10829034
  23. Sub-family selective actions in the ability of Erk2 MAP kinase to phosphorylate and regulate the activity of PDE4 cyclic AMP-specific phosphodiesterases.
    Br J Pharmacol. 2000 Oct;131(4):811-9 PMID: 11030732
  24. Action of rolipram on specific PDE4 cAMP phosphodiesterase isoforms and on the phosphorylation of cAMP-response-element-binding protein (CREB) and p38 mitogen-activated protein (MAP) kinase in U937 monocytic cells.
    Biochem J. 2000 Apr 15;347(Pt 2):571-8 PMID: 10749688
  25. mAKAP assembles a protein kinase A/PDE4 phosphodiesterase cAMP signaling module.
    EMBO J. 2001 Apr 17;20(8):1921-30 PMID: 11296225
  26. Molecular cloning, genomic positioning, promoter identification, and characterization of the novel cyclic amp-specific phosphodiesterase PDE4A10.
    Mol Pharmacol. 2001 May;59(5):996-1011 PMID: 11306681
  27. Phosphodiesterase 4D and protein kinase a type II constitute a signaling unit in the centrosomal area.
    J Biol Chem. 2001 Jun 22;276(25):21999-2002 PMID: 11285255
  28. PDE4 cAMP-specific phosphodiesterases.
    Prog Nucleic Acid Res Mol Biol. 2001;69:249-315 PMID: 11550796
  29. Phorbol 12-myristate 13-acetate triggers the protein kinase A-mediated phosphorylation and activation of the PDE4D5 cAMP phosphodiesterase in human aortic smooth muscle cells through a route involving extracellular signal regulated kinase (ERK).
    Mol Pharmacol. 2001 Nov;60(5):1100-11 PMID: 11641439
  30. Cleavage of structural proteins during the assembly of the head of bacteriophage T4.
    Nature. 1970 Aug 15;227(5259):680-5 PMID: 5432063
  31. Multiple cyclic nucleotide phosphodiesterase activities from rat brain.
    Biochemistry. 1971 Jan 19;10(2):311-6 PMID: 4321663
  32. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.
    Anal Biochem. 1976 May 7;72:248-54 PMID: 942051
  33. A peripheral and an intrinsic enzyme constitute the cyclic AMP phosphodiesterase activity of rat liver plasma membranes.
    Biochem J. 1980 May 1;187(2):381-92 PMID: 6249268
  34. Insulin exerts actions through a distinct species of guanine nucleotide regulatory protein: inhibition of adenylate cyclase.
    Biochem J. 1983 Aug 15;214(2):547-52 PMID: 6311187
  35. The mRNA encoding a high-affinity cAMP phosphodiesterase is regulated by hormones and cAMP.
    Proc Natl Acad Sci U S A. 1989 Nov;86(21):8197-201 PMID: 2554303
  36. Cyclic nucleotide phosphodiesterases: pharmacology, biochemistry and function.
    Pharmacol Ther. 1991;51(1):13-33 PMID: 1663250
  37. Glucagon, vasopressin and angiotensin all elicit a rapid, transient increase in hepatocyte protein kinase C activity.
    Biochem J. 1992 Apr 15;283 ( Pt 2):341-6 PMID: 1575678
  38. Engineered deletion of the unique N-terminal domain of the cyclic AMP-specific phosphodiesterase RD1 prevents plasma membrane association and the attainment of enhanced thermostability without altering its sensitivity to inhibition by rolipram.
    Biochem J. 1993 Jun 15;292 ( Pt 3):677-86 PMID: 7686364
  39. A family of human phosphodiesterases homologous to the dunce learning and memory gene product of Drosophila melanogaster are potential targets for antidepressant drugs.
    Mol Cell Biol. 1993 Oct;13(10):6558-71 PMID: 8413254
  40. Protein kinase A regulation of cAMP phosphodiesterase expression in rat skeletal myoblasts.
    J Biol Chem. 1994 Mar 25;269(12):8680-5 PMID: 7510696
  41. The short-term activation of a rolipram-sensitive, cAMP-specific phosphodiesterase by thyroid-stimulating hormone in thyroid FRTL-5 cells is mediated by a cAMP-dependent phosphorylation.
    J Biol Chem. 1994 Mar 25;269(12):9245-52 PMID: 8132662
  42. The ratPDE3/IVd phosphodiesterase gene codes for multiple proteins differentially activated by cAMP-dependent protein kinase.
    J Biol Chem. 1994 Jul 15;269(28):18271-4 PMID: 8034568
  43. Identification and characterization of the type-IVA cyclic AMP-specific phosphodiesterase RD1 as a membrane-bound protein expressed in cerebellum.
    Biochem J. 1995 Mar 15;306 ( Pt 3):801-9 PMID: 7702577
  44. Molecular biology of the cyclic AMP-specific cyclic nucleotide phosphodiesterases: a diverse family of regulatory enzymes.
    Cell Signal. 1994 Nov;6(8):851-9 PMID: 7718405
  45. Proposal for pharmacologically distinct conformers of PDE4 cyclic AMP phosphodiesterases.
    Cell Signal. 1997 May-Jun;9(3-4):227-36 PMID: 9218122
  46. Co-transfection with protein kinase D confers phorbol-ester-mediated inhibition on glucagon-stimulated cAMP accumulation in COS cells transfected to overexpress glucagon receptors.
    Biochem J. 1997 Sep 1;326 ( Pt 2):545-51 PMID: 9291130
  47. Characterization of five different proteins produced by alternatively spliced mRNAs from the human cAMP-specific phosphodiesterase PDE4D gene.
    Biochem J. 1997 Dec 1;328 ( Pt 2):539-48 PMID: 9371713
  48. Molecular cloning and transient expression in COS7 cells of a novel human PDE4B cAMP-specific phosphodiesterase, HSPDE4B3.
    Biochem J. 1997 Dec 1;328 ( Pt 2):549-58 PMID: 9371714
  49. Molecular cloning and expression of a human phosphodiesterase 4C.
    Cell Signal. 1997 Dec;9(8):575-85 PMID: 9429761
  50. Phosphodiesterase isozymes: molecular targets for novel antiasthma agents.
    Am J Respir Crit Care Med. 1998 Feb;157(2):351-70 PMID: 9476844
  51. The role of phosphodiesterase enzymes in allergy and asthma.
    Adv Pharmacol. 1998;44:33-89 PMID: 9547884
  52. The multienzyme PDE4 cyclic adenosine monophosphate-specific phosphodiesterase family: intracellular targeting, regulation, and selective inhibition by compounds exerting anti-inflammatory and antidepressant actions.
    Adv Pharmacol. 1998;44:225-342 PMID: 9547887
  53. cAMP-specific phosphodiesterase HSPDE4D3 mutants which mimic activation and changes in rolipram inhibition triggered by protein kinase A phosphorylation of Ser-54: generation of a molecular model.
    Biochem J. 1998 Jul 1;333 ( Pt 1):139-49 PMID: 9639573
  54. Asthma therapy for the 21st century.
    Trends Pharmacol Sci. 1998 May;19(5):160-4 PMID: 9652186
  55. Induction of phosphodiesterases 3B, 4A4, 4D1, 4D2, and 4D3 in Jurkat T-cells and in human peripheral blood T-lymphocytes by 8-bromo-cAMP and Gs-coupled receptor agonists. Potential role in beta2-adrenoreceptor desensitization.
    J Biol Chem. 1998 Aug 7;273(32):20575-88 PMID: 9685415
  56. Novel cyclic compounds as potent phosphodiesterase 4 inhibitors.
    J Med Chem. 1998 Oct 22;41(22):4216-23 PMID: 9784096
  57. The MAP kinase ERK2 inhibits the cyclic AMP-specific phosphodiesterase HSPDE4D3 by phosphorylating it at Ser579.
    EMBO J. 1999 Feb 15;18(4):893-903 PMID: 10022832
  58. Association with the SRC family tyrosyl kinase LYN triggers a conformational change in the catalytic region of human cAMP-specific phosphodiesterase HSPDE4A4B. Consequences for rolipram inhibition.
    J Biol Chem. 1999 Apr 23;274(17):11796-810 PMID: 10206997
  59. AKAPs: from structure to function.
    Trends Cell Biol. 1999 Jun;9(6):216-21 PMID: 10354567
  60. Activation of the cAMP-specific phosphodiesterase PDE4D3 by phosphorylation. Identification and function of an inhibitory domain.
    J Biol Chem. 1999 Jul 9;274(28):19677-85 PMID: 10391907
Article Info
Journal
British journal of pharmacology
Abbr.
Br J Pharmacol
ISSN
0007-1188
DOI
10.1038/sj.bjp.0704743
Published
2002-06-00
Pages
421-33
Language
English
Region
England
NLM ID
7502536
PMCID
PMC1573369
Subset
IM
Corrections
CommentIn
PMID: 12023934
External Links
PubMed source DOI: 10.1038/sj.bjp.0704743 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2